Also, Siao et al. (2022) noted that patients with T2DM treated with SGLT2 inhibitors had a low rate of diabetic complications as well as an 11% lower risk of dementia development compared with patients not using this group of drugs. Here, SLC5A2 is linked to type 2 diabetes mellitus.